The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Limitations of current risk stratification tools for SMM/MGUS
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, briefly discusses the key limitations of current risk stratification tools for smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS). The existing tools are static, focusing only on clinical factors without accounting for the dynamic progression of the disease, and lack a comprehensive biological perspective. Several groups are actively seeking to incorporate and understand these missing features. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
